Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512404 | 0.87 | MAOB (0.56) | PDGFRBPDGFRAMAOBALOX5HDAC6 | |
| SCHEMBL13535019 | 0.83 | AOC3 (0.54) | PDGFRBPDGFRAMAOBALOX5HDAC6 | |
| SCHEMBL4538153 | 0.83 | MAOB (0.67) | PDGFRBPDGFRAMAOBALOX5MAPT | |
| SCHEMBL14068434 | 0.82 | AKT1 (0.55) | MAPK1 | |
| SCHEMBL20314429 | 0.81 | MAPK1 (0.49) | PDGFRBPDGFRAMAOBALOX5HDAC6 | |
| SCHEMBL6582384 | 0.81 | CYP1A2 (0.56) | PDGFRBPDGFRAMAOBALOX5HDAC6 | |
| SCHEMBL1072784 | 0.80 | GRM5 (0.62) | MAOBGRM5ALOX5HDAC6LMNA | |
| SCHEMBL13841458 | 0.80 | GRM5 (0.62) | MAOBGRM5ALOX5HDAC6LMNA | |
| SCHEMBL20832869 | 0.79 | APP (0.53) | PDGFRBPDGFRAMAOBALOX5HDAC6 | |
| SCHEMBL7057444 | 0.79 | CHRNB2 (0.49) | PDGFRBPDGFRAMAOBALOX5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-11129827-B2 | Dual MAGL and FAAH inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3414229-B1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2019149260-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| WO-2019053427-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| WO-2017139274-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-9701635-B2 | C-H fluorination of heterocycles with silver (II) fluoride | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129827-B2 | Dual MAGL and FAAH inhibitors | FAAH, FAAH2, MAG | PDGFRB 3248/4885PDGFRA 2920/4885MAOB 46/4885 |
| US-20170204109-A1 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | PDGFRB 3596/4885PDGFRA 3664/4885MAOB 351/4885 |
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | AFF2, INF2, NPFFR2 | PDGFRB 1692/4885PDGFRA 1181/4885MAOB 2078/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | PDGFRB 3724/4885PDGFRA 3888/4885MAOB 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.